We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Minocycline to Treat Childhood Regressive Autism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00409747
Recruitment Status : Completed
First Posted : December 11, 2006
Results First Posted : December 11, 2015
Last Update Posted : December 11, 2015
Information provided by (Responsible Party):

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Autism
Regressive Autism
Intervention: Drug: Minocycline

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Referrals accepted from community physicians and self(parent) referrals.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Three subjects did not start the drug due to abnormal MRI,initial elevated liver enzymes, and and initial elevated amylase. 11 subjects began taking drug. One subject withdrew after starting drug.

Reporting Groups
Minocycline Open-label minocycline treatment at 1.4 mg/kg/day

Participant Flow:   Overall Study
Withdrawal by Subject                1 

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
10 subjects completed the trial and had analyzable data at the 6 month mark. One child had csf collected after 3 months.

Reporting Groups
Minocycline Open-label minocycline treatment at 1.4 mg/kg/day

Baseline Measures
Overall Participants Analyzed 
[Units: Participants]
[Units: Participants]
<=18 years   11 
Between 18 and 65 years   0 
>=65 years   0 
[Units: Years]
Mean (Standard Deviation)
 7.2  (2.9) 
[Units: Participants]
Female   2 
Male   9 
Region of Enrollment 
[Units: Participants]
United States   11 

  Outcome Measures

1.  Primary:   z Score   [ Time Frame: Pre and post treatment with minocyline at 6 months for 10 subjects ]

2.  Secondary:   Clinical Global Impressions Scale-Severity (CGI). (Connors & Barkley, 1985)   [ Time Frame: Baseline and 6 months ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Small, uncontrolled pilot.

  More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: Dr. Susan Swedo
Organization: NIH/NIMH/PDN Branch
phone: 301-496-5323
e-mail: swedos@mail.nih.gov

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: National Institutes of Health Clinical Center (CC) ( National Institute of Mental Health (NIMH) )
ClinicalTrials.gov Identifier: NCT00409747     History of Changes
Other Study ID Numbers: 070024
07-M-0024 ( Other Identifier: NIH Protocol number )
First Submitted: December 8, 2006
First Posted: December 11, 2006
Results First Submitted: October 22, 2012
Results First Posted: December 11, 2015
Last Update Posted: December 11, 2015